MedTrace Logo

Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis

NCT01044719 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2010-04-13

No results posted yet for this study

Summary

Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.

Conditions

Interventions

DRUG

Ceftazidime

Ceftazidime 2g TDS IV

DRUG

Tobramycin

Tobramycin 7mg/kg/day OD IV

DRUG

Meropenem

Meropenem 2g TDS IV

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Margaret Hodson, MD FRCP DA · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-10-31
Completion
2011-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044719 on ClinicalTrials.gov